# MultimodalCNN-PD: a Parkinson’s disease diagnostics framework using multimodal convolutional neural network

**Authors:** Tongle Zhi, Haonan Liu, Xuan Wang, Umar Muhammad Ibrahim, Chengjie Meng

PMC · DOI: 10.3389/fnagi.2026.1733075 · 2026-02-25

## TL;DR

This paper introduces a new AI framework that combines brain scans and patient data to accurately detect Parkinson's disease at early stages.

## Contribution

A novel multimodal deep learning framework for PD diagnosis that integrates MRI and clinical metadata with improved efficiency and accuracy.

## Key findings

- The model achieved 97.5% accuracy on the PPMI dataset for classifying normal, prodromal, and diagnosed PD cases.
- External validation on OASIS-3 showed 96.2% accuracy with strong generalizability across different populations.
- Key components like Mobile CBAM and MGCA++ significantly improved performance while reducing computational costs.

## Abstract

Parkinson’s disease (PD) is a prevalent neurodegenerative disorder that severely affects motor and cognitive functions. Early diagnosis, particularly during the prodromal phase, is critical for effective intervention.

This study presents MultimodalCNN-PD++, a deep learning model that integrates Magnetic Resonance Imaging (MRI) with clinical metadata (including motor/cognitive assessments, demographic data, and genetic biomarkers) to enhance PD classification. The model employs a lightweight EfficientNetB0 backbone, Mobile Convolutional Block Attention Modules (Mobile CBAM), and an enhanced Meta-Guided Cross-Attention (MGCA++) mechanism. A three-stage hierarchical feature selection method identifies the most discriminative clinical features, while metadata is processed with BioClinicalBERT using Low-Rank Adaptation (LoRA).

Validated on the Parkinson’s Progression Markers Initiative (PPMI) dataset, the model achieved 97.5% accuracy in distinguishing Normal Control, prodromal PD, and diagnosed PD cases, with reduced parameters and computational costs. External validation on the OASIS-3 dataset confirmed robust generalizability (96.2% accuracy) despite demographic and acquisition protocol variations. Ablation studies highlighted the contributions of Mobile CBAM, MGCA++, hierarchical feature selection, and BioClinicalBERT-LoRA.

This framework sets a new benchmark for multiclass PD diagnosis, demonstrating strong potential as a clinically deployable AI tool for early detection and personalized management of neurodegenerative diseases.

## Linked entities

- **Diseases:** Parkinson’s disease (MONDO:0005180)

## Full-text entities

- **Diseases:** PD (MESH:D010300), neurodegenerative diseases (MESH:D019636)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12975756/full.md

---
Source: https://tomesphere.com/paper/PMC12975756